Richardson Labs' Arthred-G osteoarthritis claims subject of FDA "courtesy letter".
This article was originally published in The Tan Sheet
Executive Summary
RICHARDSON LABS ARTHRED-G CARTILAGE CLAIM DRAWS "COURTESY LETTER" from FDA's Center for Food Safety & Applied Nutrition Office of Special Nutritionals. In the Aug. 6 advisory letter, FDA cites one of the company's registered "structure/function" claims for Arthred-G -- "provides proactive nutritional support for cartilage degeneration" -- which "suggests that [the product] is intended to treat, mitigate, prevent, or cure a disease, namely osteoarthritis". The claim causes the product to be classified as a drug under the FD&C Act, FDA asserts. Richardson Labs has since changed the claim to "provides nutritional support for cartilage regeneration.